# PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

> **NCT03006614** · PHASE3 · UNKNOWN · sponsor: **Shi Yanxia** · enrollment: 320 (estimated)

## Conditions studied

- Breast Cancer Model
- Effects of Chemotherapy
- Breast Cancer

## Interventions

- **DRUG:** NVB
- **DRUG:** EPI
- **DRUG:** DDP
- **DRUG:** CAP
- **DRUG:** GEM
- **DRUG:** H
- **DRUG:** CTX
- **DRUG:** T

## Key facts

- **NCT ID:** NCT03006614
- **Lead sponsor:** Shi Yanxia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-03
- **Final completion:** 2023-03
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2017-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006614, "PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03006614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*